Audited Supplier
In This Store
Category:Natural Extracts > Plant Extracts
Product Name:Nattokinase
CAS No.:133876-92-3
Standard:In-house Standards
Price(USD):Negotiable
Company:PINGYU YIMEIKANG PLANT TECHNOLOGY CO.,LTD
Grade: Pharmaceutical Grade
Factory Location: Pingyu,Henan,China
Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia
Packaging Information: 25kg/drum
Delivery Lead Time: 1 week
Sample Provided: yes
Payment Terms: T/T
| Name: NattoKinase | ||
| CAS#: 133876-92-3 | ||
| Botanical Source: Natto | ||
| Specification: 5000fu/g, 10000fu/g, 20000fu/g, 30000fu/g | ||
| Function & Application: Nattokinase (NK), also known as subtilisin, is a serine protease produced by Bacillus subtilisl natto during the fermentation of natto. It has the functions of dissolving thrombus, reducing blood viscosity, improving blood circulation, softening and increasing blood vessel elasticity. | ||
| TEST ITEM | STANDARD | RESULT |
| Appearance | Light yellow or white powder | Complies (Visual) |
| Odor | Characteristic | Complies |
| Taste | Characteristic | Complies |
| Excipient | None | Complies |
| Mesh size | 100% pass 80 mesh | Complies |
| Loss on drying | ≤8.0% | 4.3% |
| Ash content | ≤5.0% | 2.1% |
| Bulk density | 40-60g/100ml | Complies |
| Assay | ≥20000fu/g | 21500fu/g |
| HEAVY METAL | STANDARD | RESULT |
| Total | ≤10ppm | Complies |
| Lead | ≤2ppm | Complies |
| Arsenic | ≤2ppm | Complies |
| MICROBIOLOGICAL TEST | STANDARD | RESULT |
| Total microbial count | ≤3000cfu/g | Complies |
| Yeast & mold | ≤100cfu/g | Complies |
| E.Coli | Negative | Negative |
| Salmonella | Negative | Negative |
| Staphylococcus | Negative | Negative |
| Packaging: The usual packaging is 25kg net carton drum or box with a polyethylene bag in side. | ||
| Storage: Preserve in well closed,light resistant and dry environment. | ||
If you are interested, welcome contact us sales@yimeikangherb.com
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
+86 15021993094
Follow Us：
Pharma Sources Insight January 2025
